ArticleBlood advances2023

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.

Peter W M Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.